Alexion Pharmaceuticals, a New Haven, Connecticut-based biopharmaceutical company, has made further changes to its executive leadership, two months following the appointment of new chief executive officer (CEO) in March 2017.

Brian Goff is joining Alexion as chief commercial officer, effective June 1, 2017. Mr. Goff is a veteran biopharmaceutical executive with more than 25 years of experiences at companies, including Neurovance, Inc., Baxalta, Inc., Baxter, Novartis, and Johnson & Johnson. Mr. Goff will lead all commercial operations globally with responsibility for country operations in each of Alexion’s affiliates in North America, EMEA, Japan, Asia Pacific, and Latin America. He succeeds Carsten Thiel who is leaving the company to pursue new opportunities effective June 1, 2017.

Dave Anderson, chief financial officer, will resign his position at the end of August. A search for a new CFO is underway.

Martin Mackay, executive vice president and head of research & development (R&D) will be retiring from Alexion at the end of 2017.

Clare Carmichael, executive vice president and chief human resources officer, will be leaving the company to pursue new opportunities effective June 1, 2017. Recruiting is underway for a replacement.

In March 2017, Alexion appointed Ludwig N. Hantson, PhD., as CEO and member of the board of directors. Dr. Hantson most recently served as president and CEO of Baxalta, a spin-off as a public company from Baxter, He succeeded David R. Brennan, who had led the company as Interim CEO since December 2016. Mr. Brennan remains on the board of directors as chairman.

Alexion’s lead product is Soliris (eculizumab), which posted net product sales of $783 million in the first quarter of 2017 and full-year 2016 sales of $2.8 billion. It is used to treat paroxysmal nocturnal hemoglobinuria, a rare blood disorder. 

Source: Alexion Pharmaceuticals